Should Glaukos’ (GKOS) Big 2026 Sales Target and ESOP Shelf Filing Require Action From Investors?

Simply Wall St

Thu, February 26, 2026 at 5:16 PM GMT+9 3 min read

In this article:

GKOS

+1.44%

In February 2026, Glaukos Corporation reported fourth-quarter 2025 results showing sales of US$143.12 million and a net loss of US$133.66 million, including a US$112.87 million intangible asset impairment, while also filing a US$69.25 million shelf registration for 575,108 common shares related to its employee stock ownership plan and issuing 2026 sales guidance of US$600 million to US$620 million.

These updates highlight a company balancing rapid top-line expansion and a deepening product portfolio with substantial non-cash charges and ongoing operating losses, underscoring the tension between growth investment and the path toward profitability.

Next, we’ll examine how strong procedural glaucoma momentum and the new 2026 sales outlook may reshape Glaukos’ existing investment narrative.

AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there’s still time to get in early.

Glaukos Investment Narrative Recap

To own Glaukos, you need to be comfortable backing a glaucoma and corneal disease platform that is still losing money while trying to scale its newer procedures and drugs. The latest quarter keeps that trade-off front and center: solid sales, a large non cash impairment, and continued operating losses. Near term, the main catalyst remains execution in procedural glaucoma and early Epioxa uptake, while the biggest risk is that rising costs and reimbursement pressure keep profitability out of reach.

The most directly relevant update is the reaffirmed 2026 net sales guidance of US$600 million to US$620 million, coming alongside the Q4 2025 loss and impairment. That revenue outlook, if met, would further increase the size of Glaukos’ glaucoma and corneal franchise, but it also raises the stakes: any hiccup in iDose TR reimplantation, Epioxa adoption, or payer support could leave the company with higher costs and a larger loss base than many shareholders might be comfortable with.

Yet against this growth story, the scale of recent losses and the US$112.87 million impairment are signals investors should be aware of as they consider whether…

Read the full narrative on Glaukos (it’s free!)

Glaukos’ narrative projects $856.9 million revenue and $72.3 million earnings by 2028.

Uncover how Glaukos’ forecasts yield a $131.77 fair value, a 9% upside to its current price.

Exploring Other Perspectives

GKOS 1-Year Stock Price Chart

Some of the most pessimistic analysts were already wary, assuming about US$779 million of revenue and only US$46 million of earnings by 2028, highlighting how differently you and they might view risks like heavy reliance on products such as iDose and Epioxa, especially in light of the latest impairment and ongoing losses.

Story Continues  

Explore 4 other fair value estimates on Glaukos - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don’t just follow the ticker - dig into the data and build a conviction that’s truly your own.

A great starting point for your Glaukos research is our analysis highlighting 2 key rewards that could impact your investment decision.

Our free Glaukos research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Glaukos' overall financial health at a glance.

Ready For A Different Approach?

Right now could be the best entry point. These picks are fresh from our daily scans. Don’t delay:

We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Find 53 companies with promising cash flow potential yet trading below their fair value.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include GKOS.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info